Literature DB >> 21488187

Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications.

Seoung Wan Chae1, Jin Hee Sohn, Dong-Hoon Kim, Yoon Jung Choi, Yong Lai Park, Kyungeun Kim, Young Hye Cho, Jung-Soo Pyo, Jun Ho Kim.   

Abstract

PURPOSE: The molecular mechanisms that are responsible for the initiation and progression of breast cancers are largely unknown. This study was to analyze the cyclin B1, cdc2, p53 and p16 tumor suppressor genes in human breast cancer.
MATERIALS AND METHODS: To investigate the role of cyclin B1, cdc2, p53 and p16 in the pathogenesis and progression of breast carcinomas, 98 cases of breast cancers were examined by immunohistochemical method. The correlations of cyclin B1, cdc2, p53 and p16 expression with various clinico-pathologic findings were analysed.
RESULTS: In the normal breast tissues, cyclin B1, cdc2 and p16 were weakly expressed, while p53 was not expressed. On the other hand, cyclin B1, cdc2, p53 and p16 were overexpressed in breast cancer, showing correlation between the expression of cyclin B1 and cdc2 and breast cancers (p=0.00). The overexpressions of cdc2 and p16 were correlated with an infiltrative tumor border pattern and this was statistically significant (p<0.05). In addition, the overexpression of cdc2 was correlated with histologic high grade carcinomas (p=0.00).
CONCLUSION: Cyclin B1 and cdc2 appeared to be involved in the genesis or progression of breast cancers. In addition, the overexpressions of p16 and p53 may play important roles in more aggressive tumor and the overexpression of cdc2 is associated with progression of tumor to a higher grade of breast carcinomas. The deranged overexpressions of cyclin B1, cdc2, p16 and p53 may play an important role in human breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21488187      PMCID: PMC3101063          DOI: 10.3349/ymj.2011.52.3.445

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  32 in total

1.  An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.

Authors:  D M O'Hanlon; M Kiely; M MacConmara; R Al-Azzawi; Y Connolly; M Jeffers; F B Keane
Journal:  Eur J Surg Oncol       Date:  2002-03       Impact factor: 4.424

2.  Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice.

Authors:  Angela N Bartley; Dennis W Ross
Journal:  Arch Pathol Lab Med       Date:  2002-04       Impact factor: 5.534

3.  Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma.

Authors:  O J Halvorsen; J Høstmark; S Haukaas; P A Høisaeter; L A Akslen
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

4.  Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.

Authors:  J C Soria; S J Jang; F R Khuri; K Hassan; D Liu; W K Hong; L Mao
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

Review 5.  Cyclin B1 and CDK1: nuclear localization and upstream regulators.

Authors:  Lisa A Porter; Daniel J Donoghue
Journal:  Prog Cell Cycle Res       Date:  2003

6.  Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells.

Authors:  Juping Yuan; Ruilan Yan; Andrea Krämer; Frank Eckerdt; Marc Roller; Manfred Kaufmann; Klaus Strebhardt
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

7.  Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival.

Authors:  Roger M Feakins; Carole D Nickols; Heena Bidd; Sarah-Jane Walton
Journal:  Hum Pathol       Date:  2003-12       Impact factor: 3.466

8.  Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Authors:  H P Kourea; A K Koutras; C D Scopa; M N Marangos; E Tzoracoeleftherakis; D Koukouras; H P Kalofonos
Journal:  Mol Pathol       Date:  2003-12

9.  Nuclear p53 immunoreaction associated with poor prognosis of breast cancer.

Authors:  K Iwaya; H Tsuda; H Hiraide; K Tamaki; S Tamakuma; T Fukutomi; K Mukai; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1991-07

10.  Cancer statistics in Korea: incidence, mortality and survival in 2005.

Authors:  Kyu-Won Jung; Young-Joo Won; Sohee Park; Hyun-Joo Kong; Joohon Sung; Hai-Rim Shin; Eun-Cheol Park; Jin Soo Lee
Journal:  J Korean Med Sci       Date:  2009-11-07       Impact factor: 2.153

View more
  32 in total

1.  S-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers.

Authors:  Maria Lauda Tomasi; Ivan Tomasi; Komal Ramani; Rosa Maria Pascale; Jun Xu; Pasquale Giordano; José M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

2.  Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.

Authors:  Sharareh Siamakpour-Reihani; Kouros Owzar; Chen Jiang; Peter M Scarbrough; Oana I Craciunescu; Janet K Horton; Holly K Dressman; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2015-03-26       Impact factor: 3.914

3.  The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer.

Authors:  Abigail L Shearin; Benoit Hedan; Edouard Cadieu; Suzanne A Erich; Emmett V Schmidt; Daniel L Faden; John Cullen; Jerome Abadie; Erika M Kwon; Andrea Gröne; Patrick Devauchelle; Maud Rimbault; Danielle M Karyadi; Mary Lynch; Francis Galibert; Matthew Breen; Gerard R Rutteman; Catherine André; Heidi G Parker; Elaine A Ostrander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-23       Impact factor: 4.254

4.  Laryngeal squamous cell carcinoma cell lines show high tolerance for siRNA-mediated CDK1 knockdown.

Authors:  Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Adam Ustaszewski; Joanna Janiszewska; Katarzyna Kiwerska; Julia Paczkowska; Reidar Grenman; Maciej Giefing; Malgorzata Jarmuz-Szymczak
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

5.  Pathway-based analysis of breast cancer.

Authors:  Dong Song; Miao Cui; Gang Zhao; Zhimin Fan; Katherine Nolan; Ying Yang; Peng Lee; Fei Ye; David Y Zhang
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

6.  P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling.

Authors:  Le Wang; Xiangwen Zhan; Xiaomeng Shen; Mingzhe Li; Jianming Yang; Wenhua Yu; Hao Chen; Bo Jin; Zebin Mao
Journal:  Mol Cell Biochem       Date:  2018-01-31       Impact factor: 3.396

7.  Determination of whole transcription profiles and specific pathways in invasive ductal breast carcinoma.

Authors:  Pasra Arnutti; Manas Kotepui; Wichitra Asanprakit; Phaibul Punyarit; Porntip Chavalitshewinkoon-Petmitr; Talabporn Harnroongroj; Songsak Petmitr
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

8.  Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.

Authors:  Jefferson da Rocha Tenório; Leorik Pereira da Silva; Marília Gabriela de Aguiar Xavier; Thalita Santana; George João Ferreira do Nascimento; Ana Paula Veras Sobral
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-12       Impact factor: 2.503

9.  Digitoxin and its analogs as novel cancer therapeutics.

Authors:  Hosam A Elbaz; Todd A Stueckle; William Tse; Yon Rojanasakul; Cerasela Zoica Dinu
Journal:  Exp Hematol Oncol       Date:  2012-04-05

10.  p16 expression correlates with basal-like triple-negative breast carcinoma.

Authors:  Amany A Abou-Bakr; Hany I Eldweny
Journal:  Ecancermedicalscience       Date:  2013-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.